MOUNT ARLINGTON, N.J.--(BUSINESS WIRE)--PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that Paul G. Chaney, president and chief executive officer, will present topline data from the company’s Phase 1/2 clinical trial of PAN-90806 at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) on Thursday, October 10 in San Francisco. PAN-90806 is a once-daily topical formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases, including neovascular age-related macular degeneration (wet AMD).
Details of the presentation are as follows:
Session Title: Drug Delivery Spotlight
Date/Time: Thurs., Oct. 10, 2019 at 4:06 – 4:13 p.m. PT
Location: Hilton San Francisco Union Square, San Francisco
A copy of the presentation will be made available on the PanOptica website at www.panopticapharma.com.
PAN-90806 is a potent and selective inhibitor of VEGF receptor signaling. VEGF is a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two pathological processes that contribute to the vision loss associated with wet AMD. In pre-clinical research using validated ocular angiogenesis models, topically administered PAN-90806 in the form of an eye drop suppressed the formation of new blood vessels. In non-clinical pharmacokinetic studies, topical administration of PAN-90806 achieved significant and sustained levels in the retina and choroid of multiple species, supporting further investigation of PAN-90806. PanOptica is developing PAN-90806 with the goal of providing patients with wet AMD the ability to improve or maintain vision with an eye drop that is safer and less burdensome than the current treatment which relies on drug injections into the eye several times a year for the lifetime of the patient.
PanOptica, Inc., is a private biopharmaceutical company focused on developing innovative ophthalmology therapies. Investors include Third Rock Ventures and SV Health Investors. The company was co-founded by Paul Chaney, past president of OSI-Eyetech, and Martin Wax, MD, a noted academic clinician scientist working in glaucoma, and most recently vice president of research and development and head of ophthalmology discovery and pre-clinical development at Alcon Labs, Inc. The company seeks early-stage assets translated from other diseases and develops select candidates through human clinical proof of concept. For more information, please visit www.panopticapharma.com.